Bristol drug flop opens big cancer opportunity: AstraZeneca CEO

COPENHAGEN (Reuters) - The failure of Bristol-Myers Squibb's blockbuster Opdivo immunotherapy in previously untreated lung cancer patients has opened up the market for AstraZeneca, its chief executive believes.